Optimum dose of radiotherapy for chemodectomas of the middle ear

Journal Article · Tue Jul 01 00:00:00 EDT 1980 · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

DOI:https://doi.org/10.1016/0360-3016(80)90317-X· OSTI ID:6854547

Kim, J A; Elkon, D; Lim, M L; Constable, W C

Forty patients with chemodectomas of the middle ear were seen at the University of Virginia Hospital from 1932 to 1978. Surgery, post-operative radiotherapy or radiotherapy alone were the treatment modalities employed depending on the extent of the disease. These have been reviewed with regard to the clinical presentation and results of treatment with long term follow-up of 1 to 30 years. An attempt was made to determine the optimum dose of radiotherapy based on our data and reported cases in the literature. The majority of patients complaining of tinnitus, otalgia and pulsation obtained significant if not complete relief of symptoms. Cranial nerve defects, however, ofter persisted after therapy. Tumor was considered to be controlled if there was no increase in its size or progression of symptoms. Tumor control was obtained in eight of 10 early patients but only in two of seven more patients with advanced disease with total resection. Control rate with post-operative radiotherapy after subtotal resection was 85%. Radiotherapy alone was used for inoperable or recurrent tumors and control was obtained in 88% of them. In addition to our data, the radiation dose used in over 200 patients reported in the literature was analyzed. There was only a 2% recurrence rate in patients who received 4000 rad/4 weeks or higher. Twenty-two percent of patients treated with less than 4000 rad developed recurrence. The tendency is to use a lower dose of postoperative treatment and a higher dose for gross inoperable tumors. 4000 rad/4 weeks seems to be adequate for control of postoperative residual disease and no more than 5000 rad/5 weeks are required even for advanced inoperable cases. By keeping the dose below 5000 rad/5 weeks, the incidence of complications such as brain necrosis is greatly decreased.

• Research Organization: Univ. of Virginia Medical Center, Charlottesville
• OSTI ID: 6854547
• Journal Information: Int. J. Radiat. Oncol., Biol. Phys.; (United States), Vol. 6:7
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
59 BASIC BIOLOGICAL SCIENCES
AUDITORY ORGANS
BIOLOGICAL RADIATION EFFECTS
BRAIN
NEOPLASMS
RADIATION DOSES
OPTIMIZATION
RADIOTHERAPY
SIDE EFFECTS
COBALT 60
NECROSIS
PATIENTS
RADIATION SOURCE IMPLANTS
RADIOINDUCTION
RADIUM
X RADIATION
ALKALINE EARTH METALS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL EFFECTS
BODY
CENTRAL NERVOUS SYSTEM
COBALT ISOTOPES
DISEASES
DOSES
ELECTROMAGNETIC RADIATION
ELEMENTS
IMPLANTS
INTERMEDIATE MASS NUCLEI
INTERNAL CONVERSION RADIOISOTOPES
IONIZING RADIATIONS
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
MEDICINE
METALS
MINUTES LIVING RADIOISOTOPES
NERVOUS SYSTEM
NUCLEAR MEDICINE
NUCLEI
ODD-ODD NUCLEI
ORGANS
PATHOLOGICAL CHANGES
RADIATION EFFECTS
RADIATION SOURCES
RADIATIONS
RADIOISOTOPES
RADIOLOGY
SENSE ORGANS
THERAPY
YEARS LIVING RADIOISOTOPES
550603* - Medicine- External Radiation in Therapy- (1980-)
550604 - Medicine- Unsealed Radionuclides in Therapy- (1980-)
560151 - Radiation Effects on Animals- Man
551000 - Physiological Systems